INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2017

Single-dose Mucuna pruriens seed powder showed noninferior motor improvements with fewer dyskinesias and adverse events than standard levodopa/benserazide.

Eighteen patients with advanced Parkinson disease received single doses of Mucuna pruriens (MP) powder (high-dose 17.5 mg/kg, low-dose 12.5 mg/kg, or 3.5 mg/kg with benserazide), dispersible levodopa with benserazide (LD+DDCI, 3.5 mg/kg), levodopa alone (17.5 mg/kg), or placebo in randomized order. Compared to LD+DDCI, low-dose MP produced similar motor response with fewer dyskinesias and adverse events. High-dose MP induced greater motor improvement at 90 and 180 minutes, longer ON duration, fewer dyskinesias, and fewer adverse events than LD+DDCI and levodopa alone, with no differences in cardiovascular response.

Study type
Double-blind, randomized, controlled, crossover trial
Who was studied
18 patients with advanced Parkinson disease
What was measured
Motor response at 90 and 180 minutes, ON duration, adverse events, blood pressure, heart rate, dyskinesia severity

THE PAPER

Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study.

Cilia R, Laguna J, Cassani E, Cereda E, Pozzi NG, Isaias IU, Contin M, Barichella M, Pezzoli G. Neurology, 2017.

PubMed 28679598 ↗DOI 10.1212/wnl.0000000000004175 ↗

Brain & mood

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.